Andrea Charles | 06/11/2012
Decreasing profits in pharmaceuticals over the past 5 years has put manufacturing and product costs under greater scrutiny. As a result there has been an increase in the need for a reduction in the size and cost of internal manufacturing and sourcing of cheaper products from external parties. As contract manufacturing in pharmaceuticals continues to increase, Victor Coker, Director of Business Intelligence for Nice Insight, speaks to Andrea Charles from Pharma IQ, about the meth...
To continue reading this story Click Here
RECOMMENDED
Digital Transformation in Pharma: Navigating CMO Partnerships and Supply Chain Resilience
2025-01-22
Sustainability and Inclusivity in Pharma Manufacturing: Insights from AstraZeneca’s People Hub
2024-12-11
Upcoming Events
Pharmaceutical Launch Excellence Summit
2 - 3 December, 2025
UK
Register Now |
View Agenda |
Learn More